When to Proceed with Caution: Balancing Promise with Prudence in the Treatment of Urinary Incontinence

Allan B , Bell S , Husarek K . Early feasibility study to evaluate the Viveve System for female stress urinary incontinence: Interim 6-month report. J Womens Health, 2020; 29:383–389.

Yalcin I , Bump RC . The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am J Obstetr Gynecol, 2004; 191:194–197.

Press Release: Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives. Englewood, CO, Accesswire, July 22, 2019. Available at: https://www.accesswire.com/552848/Viveve-Announces-Top-line-Results-of-LIBERATE-International-Trial-for-SUI-Q2-Transition-to-New-US-Commercial-Model-and-Pursuit-of-Financial-and-Strategic-Alternatives Accessed November 2, 2019 .

Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal “rejuvenation” or vaginal cosmetic procedures: FDA safety communication. 2018. Available at: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic Accessed November 2, 2019 .